Phase 1/2Enrolling by invitation
Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT)
ImmuneNet: Quantum-Synaptic Immunotherapy Mapping
- Sponsor
- Truway Health, Inc. (Industry)
- Enrollment
- 120 planned
- Conditions
- Systemic Lupus Erythematosus; Rheumatoid Arthritis; Multiple Sclerosis; Autoimmune Diseases; Chronic Inflammatory Syndromes; Immune Dysregulation
- Interventions
- Low-Frequency Electromagnetic Resonance Therapy (LF-EMR); Sham Resonance Device (Inactive Control); Low-Dose Naltrexone (LDN)
- Ages
- children, adults, older adults
- Registry
- NCT07221565
Full record on ClinicalTrials.gov
From the registry
The ImmuneNet study is a Phase I/II clinical trial sponsored by Truway Health, Inc. It will test whether gentle, low-frequency electromagnetic resonance (LF-EMR) can influence how immune cells communicate and synchronize with each other. The goal is to see if this "quantum-synaptic" signaling effect can help stabilize immune activity and reduce the number of autoimmune flare-ups in people living with conditions such as lupus, rheumatoid arthritis, or multiple sclerosis. Participants will receive either an active or a sham (placebo) LF-EMR session three times per week for twelve weeks. Each session is completely non-invasive. Blood samples will be collected to study cytokines (immune-system messenger molecules), gene-expression patterns, and electrical field coherence among immune cells. A machine-learning system will analyze these data to predict inflammation patterns and guide individualized treatment settings. All participant data will be securely recorded and time-stamped to ensure transparency and privacy. The expected outcome of the study is a measurable reduction in…
Primary outcomes
- Change in Autoimmune Flare Frequency
History
Primary completion expected
Last registry update
Registered
Started